Aug 20, 2026 — Lyle Small: Lahjavida & a New Frontier in Cancer Treatment

Bulletin for August 20, 2026

Featured Speaker: Lyle Small

Founder & CEO, Lahjavida — Lahjavida & a New Frontier in Cancer Treatment

OPENING

Cody led the group in prayer and our speaker Lyle Small led the Pledge of Allegiance.

• Christmas Party: Proposed date is Thursday, December 10 at Patty Jewett — replacing the regular club meeting that week.

• Jazz in the Garden: The final concert of the season is Friday, August 21 at 7:00 PM — club members are attending together.

• Member notes: Four planes flew over in the morning (possibly B-22s); a personal story about visiting Bigfork, Montana, where a 10-person boat slip on Flathead Lake runs $150,000; recent news coverage on mRNA and skin cancer made today's presentation especially timely.

KEYNOTE: LYLE SMALL — LAHJAVIDA

About Lyle

Lyle Small is a Cornell-trained bioengineer, self-taught chemist, and serial inventor. He is best known outside of medicine as the inventor of the color-changing ink on the Coors Light can and as the founder of a specialty chemicals company. For the past 15 years he has poured his energy — and $2.5 million of his own money — into Lahjavida, a preclinical oncology company built around a single bold idea: what if you could deliver chemotherapy directly and only to cancer cells?

His motivation is deeply personal. His niece was diagnosed with ovarian cancer at age nine and suffered lifelong side effects from chemotherapy — including "chemo brain." His mother survived three different cancers. Those experiences fuel everything he does.

The Problem with Chemotherapy

Standard chemotherapy is indiscriminate — it attacks healthy and cancerous cells alike. The consequences are severe:

• Chemotherapy causes death in 10–15% of treated patients.

• 30–40% of survivors experience lasting side effects.

• "Chemo brain" can reduce cognitive function by 20–30 IQ points.

• Doxorubicin (widely used in breast cancer treatment) carries lifetime dose limits due to cardiotoxicity; doses approaching 1,000 mg can be fatal.

The DDC Platform — How It Works

Lahjavida's solution is the Dye–Drug Conjugate (DDC) platform. The construct works in three parts:

1. A tumor-targeting dye that selectively binds to cancer cells across 30 different cancer types.

2. A cleavable linker that remains stable in the bloodstream but is cleaved inside cancer cells by an enzyme that is overexpressed in tumors.

3. A chemotherapy payload (e.g., doxorubicin) that is activated only once inside the tumor — leaving healthy cells unharmed.

The selectivity has been demonstrated in cell culture: healthy cells show no binding signal; cancer cells light up with a strong near-infrared signal.

The technology began in 2009 as an imaging discovery — the dye was found to selectively bind cancer cells for surgical guidance, helping surgeons visualize tumor boundaries. An early attempt to attach the dye to gold nanoparticles for radiofrequency heating proved technically feasible but impractical (the required device costs approximately $10 million). The pivot to dye–chemo conjugates followed, with three patents filed over six years.

Key Results — DDC4

The lead compound DDC4 uses doxorubicin as its payload. In A549 (lung cancer) studies:

• DDC4 achieved 70% tumor inhibition vs. 31% with doxorubicin alone.

• Doxorubicin alone caused up to 15% weight loss; DDC4 showed no comparable toxicity.

• Overall: a 3.1-fold improvement in efficacy and 215% better safety profile.

Eleven DDC compounds (DDC1–DDC11) have been developed. DDC1 and DDC2 were not advanced due to limited benefit over standard chemotherapy. Three compounds have been tested in animals — all showed positive results. The current lead molecule is DDC6. Three patents have been issued; three more are under review. The patent portfolio covers the dye + cleavable linker + payload concept and 165 specific structures. AI will be used to predict new candidate structures from existing study data.

Timeline and Funding

• Pre-IND meeting with the FDA: Planned for Q4 2026. Lyle's partner estimates a 95% chance of approval.

• Human trials: Projected to begin Q1 2028.

• Funding needed: $4.2–$6 million to reach IND. Accelerant Ventures intends to create a Special Purpose Vehicle (SPV) to raise $6 million.

• Current valuation: ~$25 million. Estimated valuation at IND approval: ~$100 million.

Business Strategy

On the concern about suppression by large pharmaceutical companies, Lyle's strategy is to position Lahjavida as "Pharma's Best Friend" — not a competitor. By attaching their DDC technology to drugs approaching patent expiration, Lahjavida can effectively extend those patents by approximately 20 years, making the technology highly attractive for licensing deals. The goal is also to seek FDA Fast Track designation during Phase 1, which could halve time to market and double company value.

Cost and Accessibility

• Standard chemotherapy: ~$25,000

• Current targeted antibody-drug conjugates (ADCs): $250,000–$300,000 (due to complex biologics manufacturing)

• DDC-based treatment (projected): ~$50,000 — significantly cheaper to manufacture, store, and ship than biologics, while remaining profitable and far more accessible

Team

• CMO: Dr. Jeff Kern, National Jewish Health

• Advisor: Dr. Daniel Von Hoff — both endorse the data and contribute their time to the project

CONCLUSION

Deepak Chopra advised: "Instead of thinking outside the box, get rid of the box." Lyle Small has done exactly that — and the results may one day change the lives of millions. In 2025, more than 3 million people in the U.S. died of cancer. Because of work like Lyle's, that number has a chance to fall.

──────────────────────────────────────────────────

The Pikes Peak Club · pikespeakclub.com